Dabur Shares to Trade Ex-Date on July 18: Final Dividend of ₹5.25

On July 18, 2025, Dabur shares will trade ex-date, meaning that the shareholders registered in the company’s books will be eligible for the cumulative ₹5.25 final dividend.

Dabur Ltd said in an exchange filing, “the Board of Directors of the Company in its meeting held on May 7, 2025, had recommended Final Dividend of Rs. 5. 25 per share (525%) for the Financial Year 2024-25. Pursuant to provisions of Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Book Closure from Monday, July 21 , 2025 to Friday, July 25, 2025 (both days inclusive). The Record date is July 18, 2025 for ascertainment of shareholders entitled to receive the dividend, if approved by the shareholders at the ensuing Annual General Meeting (AGM) to be held on Thursday, August 7, 2025.”

Also Read: Upcoming Dividends in July 2025: Nestle India, Biocon, BHEL, TCS, Blue Star & More

Dabur Q1FY26 Business Update

During the Q1FY26, the Indian FMCG sector experienced a gradual revival in demand, marked by a notable improvement in volume growth, particularly across urban markets. Dabur’s Home and Personal Care (HPC) segment is poised for a strong performance, bolstered by key categories such as oral care, home care, and skin care. Flagship brands like Dabur Red Toothpaste, Odonil, Odomos, and Gulabari are expected to deliver solid growth along with continued market share gains.

In the healthcare segment, products like Dabur Honey, Hajmola, Dabur Honitus, and Dabur Health Juices are projected to register healthy double-digit growth, with Dabur Honitus expected to exceed expectations, delivering over 40% growth. On the distribution front, organised channels—including E-commerce, Quick Commerce, and Modern Trade—sustained their growth trajectory, contributing positively to the overall business momentum.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.